EMA extends indication for darunavir/r to include adolescents >12 years
EMA monthly review
On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the indication for daruavir/r to adolescents age 12 and older who weigh >40 kg.
For full details please see the updated summary of product characteristics.
Darunavir/r is marketed by Janssen-Cilag with the trade name Prezista.
This article was originally posted on 25 August 2020.